ERBB2 and breast cancer: Preclinical data from the TRINITI-1 (NCT02732119) (Study Details Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.